92 related articles for article (PubMed ID: 10932511)
41. Comparison of two hormone replacement regimens--influence on lipoproteins and bone mineral content.
Hirvonen E; Elliesen J; Schmidt-Gollwitzer K
Maturitas; 1990 Jun; 12(2):127-36. PubMed ID: 2147736
[TBL] [Abstract][Full Text] [Related]
42. Progestogens: therapeutic and adverse effects in early post-menopausal women.
Marslew U; Riis B; Christiansen C
Maturitas; 1991 Mar; 13(1):7-16. PubMed ID: 1830636
[TBL] [Abstract][Full Text] [Related]
43. Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel.
Vejtorp M; Christensen MS; Vejtorp L; Larsen JF
Acta Obstet Gynecol Scand; 1986; 65(5):391-5. PubMed ID: 3535357
[TBL] [Abstract][Full Text] [Related]
44. [Clinical effects of hormone replacement therapy with estradiol valerate and cyproterone acetate in perimenopausal women].
Tinelli FG; Tinelli A; Sena T
Minerva Ginecol; 2002 Feb; 54(1):67-73. PubMed ID: 11828273
[TBL] [Abstract][Full Text] [Related]
45. Long-term post-menopausal hormone therapy and serum HDL-C, total cholesterol and triglycerides.
Vilska S; Punnonen R; Rauramo L
Maturitas; 1983 Aug; 5(2):97-104. PubMed ID: 6415365
[TBL] [Abstract][Full Text] [Related]
46. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.
Ottosson UB; Johansson BG; von Schoultz B
Am J Obstet Gynecol; 1985 Mar; 151(6):746-50. PubMed ID: 3976784
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic trend in acne associated with the menstrual cycle].
Cersosimo L; Iannucci D; Consalvo F; Orgiu G
Clin Ter; 1983 Jun; 105(5):411-4. PubMed ID: 6223780
[No Abstract] [Full Text] [Related]
48. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
[TBL] [Abstract][Full Text] [Related]
49. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa.
Mortimer PS; Dawber RP; Gales MA; Moore RA
Br J Dermatol; 1986 Sep; 115(3):263-8. PubMed ID: 2944534
[TBL] [Abstract][Full Text] [Related]
50. Changes in serum lipids during treatment with norgestrel, oestradiol-valerate and cycloprogynon.
Nielsen FH; Honoré E; Kristoffersen K; Secher NJ; Pedersen GT
Acta Obstet Gynecol Scand; 1977; 56(4):367-70. PubMed ID: 602705
[TBL] [Abstract][Full Text] [Related]
51. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
52. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
53. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.
Paoletti AM; Floris S; Mannias M; Orrù M; Crippa D; Orlandi R; Del Zompo M M; Melis GB
J Clin Endocrinol Metab; 2001 Feb; 86(2):608-12. PubMed ID: 11158017
[TBL] [Abstract][Full Text] [Related]
54. [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author's transl)].
Spona J; Lunglmayr G
Wien Klin Wochenschr; 1980 Jul; 92(14):494-7. PubMed ID: 6933738
[TBL] [Abstract][Full Text] [Related]
55. Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy.
Riis BJ; Jensen J; Christiansen C
Clin Endocrinol (Oxf); 1987 Mar; 26(3):327-34. PubMed ID: 2820619
[TBL] [Abstract][Full Text] [Related]
56. Endocrine effects in Asian postmenopausal women, treated with SH D 461 M and Prempak-C.
Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
Maturitas; 1995 Jan; 21(1):17-25. PubMed ID: 7731378
[TBL] [Abstract][Full Text] [Related]
57. [Replacement hormonal therapy: effects on ECG parameters in postmenopausal women].
Zatikian EP; Smetnik VP; Klimenchenko NI
Ter Arkh; 1998; 70(10):33-7. PubMed ID: 9864801
[TBL] [Abstract][Full Text] [Related]
58. [Hormone treatment in menopause].
Schindler AE
MMW Munch Med Wochenschr; 1980 Jun; 122(26):967-9. PubMed ID: 6775194
[No Abstract] [Full Text] [Related]
59. Cyproterone acetate could counteract the benefits of estradiol valerate in oophorectomized cholesterol-fed rabbits.
Sanjuán A; Castelo-Branco C; Vicente JJ; Ascaso C; Ordi J; Casals E; Mercadé I; Escaramís G; Vanrell JA
Menopause; 2002; 9(4):282-7. PubMed ID: 12082364
[TBL] [Abstract][Full Text] [Related]
60. [Antiandrogen treatment with cyproterone acetate in with virilizing symptoms].
Abrahamsson L; Hackl H; Lindström B; Martinik J
Lakartidningen; 1981 Nov; 78(47):4259-61. PubMed ID: 6460145
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
